An Open-Label Phase II Trial of Neratinib Plus Capecitabine in Subjects with HER2-Negative Metastatic Breast Cancer with Brain Metastases and Abnormally Active HER2 Signaling

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Capecitabine (Primary) ; Neratinib (Primary)
Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; Male breast cancer
Focus Therapeutic Use

11 Oct 2024 Planned End Date changed from 1 Sep 2025 to 1 Sep 2027.
11 Oct 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2026.
10 Dec 2022 Trial design presented at the 45th Annual San Antonio Breast Cancer Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com